Biogen Pops After Asking FDA To Approve Controversial Alzheimer's DrugInvestors Business Daily • 07/08/20
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s DiseaseGlobeNewsWire • 07/08/20
Biogen's Statistical Gymnastics And PR Maneuvering Will Likely Turn Aducanumab Straw Into Mega Blockbuster GoldSeeking Alpha • 06/24/20
Biogen Inc. (BIIB) Management Presents at SVB Leerink's CybeRx Series: 2nd Annual CNS Forum Conference (Transcript)Seeking Alpha • 06/23/20
Why A Patent Battle Is Leaving Biogen Staring At A Revenue PitfallInvestors Business Daily • 06/22/20